Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

So what's new with jun?

A S Kraft1

  • 1Division of Hematology/Oncology, University of Alabama, Birmingham 35294.

The American Journal of the Medical Sciences
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Nuclear oncogenes like jun and fos enhance gene transcription by forming heterodimers that bind DNA. A 30-amino acid deletion in jun protein may cause uncontrolled transcription, driving cancer cell growth and offering new chemotherapy targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing.

Oncogene·2014
Same author

Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.

Carcinogenesis·2008
Same author

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas.

Sarcoma·2008
Same author

Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A.

Oncogene·2007
Same author

A novel mitogen-activated protein kinase phosphatase is an important negative regulator of lipopolysaccharide-mediated c-Jun N-terminal kinase activation in mouse macrophage cell lines.

Molecular and cellular biology·2001
Same author

Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis.

The Journal of biological chemistry·2001
Same journal

Providers' Perspectives on Hospital-Based Tobacco Treatment Efforts.

The American journal of the medical sciences·2026
Same journal

In Memoriam: Maurice A. Mufson, MD, MACP.

The American journal of the medical sciences·2026
Same journal

Outcomes of Acute Myeloid Leukemia Patients Admitted to the Intensive Care Unit within 100 days of Allogeneic Hematopoietic Stem Cell Transplantation.

The American journal of the medical sciences·2026
Same journal

Association Between Reverse Triiodothyronine and Cardiac Complications in Patients with Uncontrolled Graves' Disease.

The American journal of the medical sciences·2026
Same journal

Chlorthalidone vs. hydrochlorothiazide in hypertension management: Lessons for guiding clinical practice.

The American journal of the medical sciences·2026
Same journal

The impact of COVID-19 on alcohol-associated hepatitis and alcohol-associated cirrhosis.

The American journal of the medical sciences·2026
See all related articles

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • Oncogenes are key drivers of cancer, with nuclear oncogenes' functions being less understood than plasma membrane-associated ones.
  • The jun and fos proto-oncogenes are nuclear proteins implicated in cancer development.

Purpose of the Study:

  • To elucidate the nuclear function of jun and fos proto-oncogenes in gene transcription.
  • To investigate the mechanism by which jun protein becomes oncogenic.

Main Methods:

  • Analysis of jun and fos proto-oncogene products.
  • Investigation of protein-DNA interactions and gene transcription activation.
  • Characterization of structural differences between normal and transforming jun proteins.

Related Experiment Videos

Main Results:

  • Jun and fos proteins form heterodimers that bind specific DNA sequences, enhancing gene transcription and messenger RNA production.
  • Transforming jun protein lacks 30 amino acids present in normal jun protein.
  • These 30 amino acids appear to bind an inhibitor, preventing jun from activating transcription.

Conclusions:

  • Unrestrained transcription activation, potentially mediated by altered jun protein, may drive cellular transformation.
  • These findings identify potential therapeutic targets for inhibiting cancer cell proliferation.